{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:07:37Z","timestamp":1785402457494,"version":"3.56.0"},"reference-count":194,"publisher":"IMR Press","issue":"7","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br. J. Hosp. Med. (Lond)"],"abstract":"<jats:p>Chronic kidney disease-associated cardiomyopathy (CKD-CM) is a term that captures the spectrum of myocardial disease that begins early in chronic kidney disease (CKD) and progresses as kidney function declines. Historically described as uremic cardiomyopathy, the condition was associated with severe left ventricular hypertrophy and fibrosis in patients with kidney failure. However, functional abnormalities and myocardial injury have been shown to begin much earlier, with diffuse interstitial fibrosis preceding overt hypertrophy or reduced ejection fraction. Fibrosis drives heart failure with preserved ejection fraction (HFpEF)-like physiology and atrial fibrillation and increases arrhythmic risk. In this review, we describe the multiple interacting mechanisms, including abnormal loading, neurohormonal activation, metabolic and inflammatory stress, mineral bone disorder, and microvascular dysfunction. We summarize imaging findings across CKD stages and describe established and emerging therapeutic strategies. A better understanding of CKD-CM pathogenesis is likely to enable early intervention and prevention, with successful outcomes measured by reduced progression to severe cardiomyopathy and lower cardiovascular mortality in CKD.<\/jats:p>","DOI":"10.31083\/bjhm51534","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:59:43Z","timestamp":1785398383000},"source":"Crossref","is-referenced-by-count":0,"title":["Chronic Kidney Disease-Associated Cardiomyopathy: Mechanisms and Therapeutic Strategies"],"prefix":"10.31083","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6739-1024","authenticated-orcid":true,"given":"Konstantinos","family":"Grigoriou","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8533-6117","authenticated-orcid":true,"given":"Vasileios","family":"Lamprou","sequence":"additional","affiliation":[{"name":"Manchester Heart Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, M13 9WL Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5233-8076","authenticated-orcid":true,"given":"Anastasios","family":"Chatzichidiroglou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, International Hellenic University, 57001 Thermi, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9260-6306","authenticated-orcid":true,"given":"Panagiotis","family":"Theofilis","sequence":"additional","affiliation":[{"name":"First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5768-9125","authenticated-orcid":true,"given":"Panagiotis","family":"Iliakis","sequence":"additional","affiliation":[{"name":"First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2616-7952","authenticated-orcid":true,"given":"Anastasios","family":"Apostolos","sequence":"additional","affiliation":[{"name":"First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"},{"name":"Department of Cardiology, Harefield Hospital, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, UB9 6JH London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0995-7015","authenticated-orcid":true,"given":"Nikolaos","family":"Ktenopoulos","sequence":"additional","affiliation":[{"name":"First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8328-5942","authenticated-orcid":true,"given":"Efstratios","family":"Karagiannidis","sequence":"additional","affiliation":[{"name":"Emergency Department, AHEPA University General Hospital of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6604-5581","authenticated-orcid":true,"given":"Antonios P.","family":"Antoniadis","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7158-4950","authenticated-orcid":true,"given":"Nikolaos","family":"Fragakis","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6899-684X","authenticated-orcid":true,"given":"Dimitrios","family":"Patoulias","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5713","authenticated-orcid":true,"given":"Paschalis","family":"Karakasis","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney International Supplements. 2022; 12: 7\u201311.","DOI":"10.1016\/j.kisu.2021.11.003"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Shahbazi F, Doosti-Irani A, Soltanian A, Poorolajal J. Global trends and projection of aetiology-based chronic kidney disease incidence from 1990 to 2030: a Bayesian age-period-cohort modelling study. BMJ Open. 2025; 15: e088104.","DOI":"10.1136\/bmjopen-2024-088104"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021; 143: 1157\u20131172.","DOI":"10.1161\/CIRCULATIONAHA.120.050686"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Chapter 1: Definition and classification of CKD. Kidney International Supplements. 2013; 3: 19\u201362.","DOI":"10.1038\/kisup.2012.64"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Marx-Sch\u00fctt K, Cherney DZI, Jankowski J, Matsushita K, Nardone M, Marx N. Cardiovascular disease in chronic kidney disease. European Heart Journal. 2025; 46: 2148\u20132160.","DOI":"10.1093\/eurheartj\/ehaf167"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Mul\u00e8 G, Castiglia A, Cusumano C, Scaduto E, Geraci G, Altieri D, et al. Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria. Advances in Experimental Medicine and Biology. 2017; 956: 279\u2013306.","DOI":"10.1007\/5584_2016_85"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Dobre MA, Ahlawat S, Schelling JR. Chronic kidney disease associated cardiomyopathy: recent advances and future perspectives. Current Opinion in Nephrology and Hypertension. 2024; 33: 203\u2013211.","DOI":"10.1097\/MNH.0000000000000952"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Garikapati K, Goh D, Khanna S, Echampati K. Uraemic Cardiomyopathy: A Review of Current Literature. Clinical Medicine Insights. Cardiology. 2021; 15: 1179546821998347.","DOI":"10.1177\/1179546821998347"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Izumaru K, Hata J, Nakano T, Nakashima Y, Nagata M, Fukuhara M, et al. Reduced Estimated GFR and Cardiac Remodeling: A Population-Based Autopsy Study. American Journal of Kidney Diseases. 2019; 74: 373\u2013381.","DOI":"10.1053\/j.ajkd.2019.02.013"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Mall G, Huther W, Schneider J, Lundin P, Ritz E. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrology, Dialysis, Transplantation. 1990; 5: 39\u201344.","DOI":"10.1093\/ndt\/5.1.39"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Aoki J, Ikari Y, Nakajima H, Mori M, Sugimoto T, Hatori M, et al. Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney International. 2005; 67: 333\u2013340.","DOI":"10.1111\/j.1523-1755.2005.00086.x"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Junho CVC, Frisch J, Soppert J, Wollenhaupt J, Noels H. Cardiomyopathy in chronic kidney disease: clinical features, biomarkers and the contribution of murine models in understanding pathophysiology. Clinical Kidney Journal. 2023; 16: 1786\u20131803.","DOI":"10.1093\/ckj\/sfad085"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Narayanan G, Halim A, Hu A, Avin KG, Lu T, Zehnder D, et al. Molecular Phenotyping and Mechanisms of Myocardial Fibrosis in Advanced Chronic Kidney Disease. Kidney360. 2023; 4: 1562\u20131579.","DOI":"10.34067\/KID.0000000000000276"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Chen C, Xie C, Wu H, Wu L, Zhu J, Mao H, et al. Uraemic Cardiomyopathy in Different Mouse Models. Frontiers in Medicine. 2021; 8: 690517.","DOI":"10.3389\/fmed.2021.690517"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Chue CD, Townend JN, Steeds RP, Ferro CJ. Arterial stiffness in chronic kidney disease: causes and consequences. Heart. 2010; 96: 817\u2013823.","DOI":"10.1136\/hrt.2009.184879"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Moody WE, Edwards NC, Chue CD, Ferro CJ, Townend JN. Arterial disease in chronic kidney disease. Heart. 2013; 99: 365\u2013372.","DOI":"10.1136\/heartjnl-2012-302818"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Gu\u00e9rin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrology, Dialysis, Transplantation. 2000; 15: 1014\u20131021.","DOI":"10.1093\/ndt\/15.7.1014"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Stomp\u00f3r T. Coronary artery calcification in chronic kidney disease: An update. World Journal of Cardiology. 2014; 6: 115\u2013129.","DOI":"10.4330\/wjc.v6.i4.115"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Raggi P. Cardiovascular disease: Coronary artery calcification predicts risk of CVD in patients with CKD. Nature Reviews. Nephrology. 2017; 13: 324\u2013326.","DOI":"10.1038\/nrneph.2017.61"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Kim GH. Primary Role of the Kidney in Pathogenesis of Hypertension. Life. 2024; 14: 119.","DOI":"10.3390\/life14010119"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Marques Vidas M, Portol\u00e9s J, Cobo M, Gorriz JL, Nu\u00f1ez J, Cases A. Anemia Management in the Cardiorenal Patient: A Nephrological Perspective. Journal of the American Heart Association. 2025; 14: e037363.","DOI":"10.1161\/JAHA.124.037363"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Scholz SS, Vukadinovi\u0107 D, Lauder L, Ewen S, Ukena C, Townsend RR, et al. Effects of Arteriovenous Fistula on Blood Pressure in Patients With End-Stage Renal Disease: A Systematic Meta-Analysis. Journal of the American Heart Association. 2019; 8: e011183.","DOI":"10.1161\/JAHA.118.011183"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Zhang F, Liu H, Liu D, Liu Y, Li H, Tan X, et al. Effects of RAAS Inhibitors in Patients with Kidney Disease. Current Hypertension Reports. 2017; 19: 72.","DOI":"10.1007\/s11906-017-0771-9"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Kaur J, Young BE, Fadel PJ. Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms. International Journal of Molecular Sciences. 2017; 18: 1682.","DOI":"10.3390\/ijms18081682"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Verma K, Pant M, Paliwal S, Dwivedi J, Sharma S. An Insight on Multicentric Signaling of Angiotensin II in Cardiovascular system: A Recent Update. Frontiers in Pharmacology. 2021; 12: 734917.","DOI":"10.3389\/fphar.2021.734917"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovascular Research. 2004; 63: 423\u2013432.","DOI":"10.1016\/j.cardiores.2004.04.030"},{"key":"ref27","unstructured":"Ai F, Chen M, Yu B, Yang Y, Xu G, Gui F, et al. Berberine regulates proliferation, collagen synthesis and cytokine secretion of cardiac fibroblasts via AMPK-mTOR-p70S6K signaling pathway. International Journal of Clinical and Experimental Pathology. 2015; 8: 12509\u201312516."},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Suematsu Y, Jing W, Nunes A, Kashyap ML, Khazaeli M, Vaziri ND, et al. LCZ696 (Sacubitril\/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease. Journal of Cardiac Failure. 2018; 24: 266\u2013275.","DOI":"10.1016\/j.cardfail.2017.12.010"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Esaki M, et al. Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure. Journal of Cardiac Failure. 2007; 13: 155\u2013162.","DOI":"10.1016\/j.cardfail.2006.11.005"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB Journal. 2006; 20: 1546\u20131548.","DOI":"10.1096\/fj.05-4642fje"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. Journal of Molecular and Cellular Cardiology. 2000; 32: 865\u2013879.","DOI":"10.1006\/jmcc.2000.1129"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Mohamed RMSM, Elshazly SM, Nafea OE, Abd El Motteleb DM. Comparative cardioprotective effects of carvedilol versus atenolol in a rat model of cardiorenal syndrome type 4. Naunyn-Schmiedeberg's Archives of Pharmacology. 2021; 394: 2117\u20132128.","DOI":"10.1007\/s00210-021-02130-1"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Yagi H, Toyama T, Kasama S, Koitabashi N, Arai M, Yokoyama T, et al. Relation between connective tissue growth factor and cardiac sympathetic nerve activity in heart failure in DCM patients. International Heart Journal. 2012; 53: 282\u2013286.","DOI":"10.1536\/ihj.53.282"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"B\u00fcrger A, Benicke M, Deten A, Zimmer HG. Catecholamines stimulate interleukin-6 synthesis in rat cardiac fibroblasts. American Journal of Physiology. Heart and Circulatory Physiology. 2001; 281: H14\u2013H21.","DOI":"10.1152\/ajpheart.2001.281.1.H14"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Wang J, Wang Y, Zhang W, Zhao X, Chen X, Xiao W, et al. Phenylephrine promotes cardiac fibroblast proliferation through calcineurin-NFAT pathway. Frontiers in Bioscience (Landmark Edition). 2016; 21: 502\u2013513.","DOI":"10.2741\/4405"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Sandroni PB, Fisher-Wellman KH, Jensen BC. Adrenergic Receptor Regulation of Mitochondrial Function in Cardiomyocytes. Journal of Cardiovascular Pharmacology. 2022; 80: 364\u2013377.","DOI":"10.1097\/FJC.0000000000001241"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Hermida N, Michel L, Esfahani H, Dubois-Deruy E, Hammond J, Bouzin C, et al. Cardiac myocyte \u03b23-adrenergic receptors prevent myocardial fibrosis by modulating oxidant stress-dependent paracrine signaling. European Heart Journal. 2018; 39: 888\u2013898.","DOI":"10.1093\/eurheartj\/ehx366"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Curaj A, Vanholder R, Loscalzo J, Quach K, Wu Z, Jankowski V, et al. Cardiovascular Consequences of Uremic Metabolites: an Overview of the Involved Signaling Pathways. Circulation Research. 2024; 134: 592\u2013613.","DOI":"10.1161\/CIRCRESAHA.123.324001"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Yang K, Xu X, Nie L, Xiao T, Guan X, He T, et al. Indoxyl sulfate induces oxidative stress and hypertrophy in cardiomyocytes by inhibiting the AMPK\/UCP2 signaling pathway. Toxicology Letters. 2015; 234: 110\u2013119.","DOI":"10.1016\/j.toxlet.2015.01.021"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? European Heart Journal. 2010; 31: 1771\u20131779.","DOI":"10.1093\/eurheartj\/ehp574"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Rana I, Kompa AR, Skommer J, Wang BH, Lekawanvijit S, Kelly DJ, et al. Contribution of microRNA to pathological fibrosis in cardio-renal syndrome: impact of uremic toxins. Physiological Reports. 2015; 3: e12371.","DOI":"10.14814\/phy2.12371"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Han H, Zhu J, Zhu Z, Ni J, Du R, Dai Y, et al. p-Cresyl sulfate aggravates cardiac dysfunction associated with chronic kidney disease by enhancing apoptosis of cardiomyocytes. Journal of the American Heart Association. 2015; 4: e001852.","DOI":"10.1161\/JAHA.115.001852"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Melhem NJ, Chajadine M, Gomez I, Howangyin KY, Bouvet M, Knosp C, et al. Endothelial Cell Indoleamine 2, 3-Dioxygenase 1 Alters Cardiac Function After Myocardial Infarction Through Kynurenine. Circulation. 2021; 143: 566\u2013580.","DOI":"10.1161\/CIRCULATIONAHA.120.050301"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Lee LYH, Oldham WM, He H, Wang R, Mulhern R, Handy DE, et al. Interferon-\u03b3 Impairs Human Coronary Artery Endothelial Glucose Metabolism by Tryptophan Catabolism and Activates Fatty Acid Oxidation. Circulation. 2021; 144: 1612\u20131628.","DOI":"10.1161\/CIRCULATIONAHA.121.053960"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Metghalchi S, Ponnuswamy P, Simon T, Haddad Y, Laurans L, Cl\u00e9ment M, et al. Indoleamine 2,3-Dioxygenase Fine-Tunes Immune Homeostasis in Atherosclerosis and Colitis through Repression of Interleukin-10 Production. Cell Metabolism. 2015; 22: 460\u2013471.","DOI":"10.1016\/j.cmet.2015.07.004"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Trant J, Lowery JB, Morales-Sosa P, Blanco G. Na,K-ATPase mediated and cardiotonic induced signaling in health and disease. Frontiers in Physiology. 2025; 16: 1694027.","DOI":"10.3389\/fphys.2025.1694027"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Pavlovic D. The role of cardiotonic steroids in the pathogenesis of cardiomyopathy in chronic kidney disease. Nephron. Clinical Practice. 2014; 128: 11\u201321.","DOI":"10.1159\/000363301"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Pavlovic D. Endogenous cardiotonic steroids and cardiovascular disease, where to next? Cell Calcium. 2020; 86: 102156.","DOI":"10.1016\/j.ceca.2019.102156"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Carullo N, Fabiano G, D'Agostino M, Zicarelli MT, Musolino M, Presta P, et al. New Insights on the Role of Marinobufagenin from Bench to Bedside in Cardiovascular and Kidney Diseases. International Journal of Molecular Sciences. 2023; 24: 11186.","DOI":"10.3390\/ijms241311186"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, et al. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension. 2006; 47: 488\u2013495.","DOI":"10.1161\/01.HYP.0000202594.82271.92"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Kielstein JT, Veldink H, Martens-Lobenhoffer J, Haller H, Perthel R, Lovric S, et al. Unilateral nephrectomy causes an abrupt increase in inflammatory mediators and a simultaneous decrease in plasma ADMA: a study in living kidney donors. American Journal of Physiology. Renal Physiology. 2011; 301: F1042\u2013F1046.","DOI":"10.1152\/ajprenal.00640.2010"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Su H, Lei CT, Zhang C. Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Frontiers in Immunology. 2017; 8: 405.","DOI":"10.3389\/fimmu.2017.00405"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Mel\u00e9ndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010; 56: 225\u2013231.","DOI":"10.1161\/HYPERTENSIONAHA.109.148635"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Zhang Y, Wang JH, Zhang YY, Wang YZ, Wang J, Zhao Y, et al. Deletion of interleukin-6 alleviated interstitial fibrosis in streptozotocin-induced diabetic cardiomyopathy of mice through affecting TGF\u03b21 and miR-29 pathways. Scientific Reports. 2016; 6: 23010.","DOI":"10.1038\/srep23010"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Li X, Wu X, Chen X, Peng S, Chen S, Zhou G, et al. Selective blockade of interleukin 6 trans-signaling depresses atrial fibrillation. Heart Rhythm. 2023; 20: 1759\u20131770.","DOI":"10.1016\/j.hrthm.2023.08.026"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Widjaja AA, Cook SA. The Pathobiology of IL-11 in Kidney Disease: From Epithelial Cell to Fibroblast and Back Again. The American Journal of Pathology. 2023; 193: 1910\u20131913.","DOI":"10.1016\/j.ajpath.2023.09.011"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Schafer S, Viswanathan S, Widjaja AA, Lim WW, Moreno-Moral A, DeLaughter DM, et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature. 2017; 552: 110\u2013115.","DOI":"10.1038\/nature24676"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Taguchi S, Azushima K, Yamaji T, Urate S, Suzuki T, Abe E, et al. Effects of tumor necrosis factor-\u03b1 inhibition on kidney fibrosis and inflammation in a mouse model of aristolochic acid nephropathy. Scientific Reports. 2021; 11: 23587.","DOI":"10.1038\/s41598-021-02864-1"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Henedak NT, El-Abhar HS, Soubh AA, Abdallah DM. NLRP3 Inflammasome: A central player in renal pathologies and nephropathy. Life Sciences. 2024; 351: 122813.","DOI":"10.1016\/j.lfs.2024.122813"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Chin LH, Hsu YJ, Hsu SC, Chen YH, Chang YL, Huang SM, et al. The regulation of NLRP3 inflammasome expression during the development of cardiac contractile dysfunction in chronic kidney disease. Oncotarget. 2017; 8: 113303\u2013113317.","DOI":"10.18632\/oncotarget.22964"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Song J, Navarro-Garcia JA, Wu J, Saljic A, Abu-Taha I, Li L, et al. Chronic kidney disease promotes atrial fibrillation via inflammasome pathway activation. The Journal of Clinical Investigation. 2023; 133: e167517.","DOI":"10.1172\/JCI167517"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Xu Y, Ren Y, Zou W, Wang M, Ye X, Shen W. Neutrophil extracellular traps aggravate uremic cardiomyopathy by inducing myocardial fibroblast pyroptosis. Scientific Reports. 2025; 15: 17509.","DOI":"10.1038\/s41598-025-02383-3"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Taylor D, Bhandari S, Seymour AML. Mitochondrial dysfunction in uremic cardiomyopathy. American Journal of Physiology. Renal Physiology. 2015; 308: F579\u2013F587.","DOI":"10.1152\/ajprenal.00442.2014"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Williams MJ, Halabi CM, Patel HM, Joseph Z, McCommis K, Weinheimer C, et al. In chronic kidney disease altered cardiac metabolism precedes cardiac hypertrophy. American Journal of Physiology. Renal Physiology. 2024; 326: F751\u2013F767.","DOI":"10.1152\/ajprenal.00416.2023"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Lesnefsky EJ, Chen Q, Tandler B, Hoppel CL. Mitochondrial Dysfunction and Myocardial Ischemia-Reperfusion: Implications for Novel Therapies. Annual Review of Pharmacology and Toxicology. 2017; 57: 535\u2013565.","DOI":"10.1146\/annurev-pharmtox-010715-103335"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Amann K, Neus\u00fcss R, Ritz E, Irzyniec T, Wiest G, Mall G. Changes of vascular architecture independent of blood pressure in experimental uremia. American Journal of Hypertension. 1995; 8: 409\u2013417.","DOI":"10.1016\/0895-7061(94)00248-a"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G. Reduced capillary density in the myocardium of uremic rats--a stereological study. Kidney International. 1992; 42: 1079\u20131085.","DOI":"10.1038\/ki.1992.390"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Charytan DM, Shelbert HR, Di Carli MF. Coronary microvascular function in early chronic kidney disease. Circulation. Cardiovascular Imaging. 2010; 3: 663\u2013671.","DOI":"10.1161\/CIRCIMAGING.110.957761"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Bajaj NS, Singh A, Zhou W, Gupta A, Fujikura K, Byrne C, et al. Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney Impairment. Circulation. 2020; 141: 21\u201333.","DOI":"10.1161\/CIRCULATIONAHA.119.043916"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Roumeliotis S, Mallamaci F, Zoccali C. Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update. Journal of Clinical Medicine. 2020; 9: 2359.","DOI":"10.3390\/jcm9082359"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Querfeld U, Mak RH, Pries AR. Microvascular disease in chronic kidney disease: the base of the iceberg in cardiovascular comorbidity. Clinical Science. 2020; 134: 1333\u20131356.","DOI":"10.1042\/CS20200279"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Law JP, Price AM, Pickup L, Radhakrishnan A, Weston C, Jones AM, et al. Clinical Potential of Targeting Fibroblast Growth Factor-23 and \u03b1Klotho in the Treatment of Uremic Cardiomyopathy. Journal of the American Heart Association. 2020; 9: e016041.","DOI":"10.1161\/JAHA.120.016041"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Amann K, Ritz E, Wiest G, Klaus G, Mall G. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. Journal of the American Society of Nephrology. 1994; 4: 1814\u20131819.","DOI":"10.1681\/ASN.V4101814"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-Arias L, Panizo-Garc\u00eda S, Mart\u00edn-V\u00edrgala J, Mart\u00edn-Carro B, Fern\u00e1ndez-Villabrille S, Avello-Llano N, et al. Contribution of phosphorus and PTH to the development of cardiac hypertrophy and fibrosis in an experimental model of chronic renal failure. Nefrologia. 2021; 41: 640\u2013651.","DOI":"10.1016\/j.nefroe.2021.12.004"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Edwards NC, Pavlovic D, Ferro CJ, Townend JN. Chronic kidney disease-associated cardiomyopathy: clinical features, pathophysiology and treatment. Nature Reviews. Cardiology. 2026; 23: 392\u2013406.","DOI":"10.1038\/s41569-025-01234-y"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Navarro-Garc\u00eda JA, Delgado C, Fern\u00e1ndez-Velasco M, Val-Blasco A, Rodr\u00edguez-S\u00e1nchez E, Aceves-Ripoll J, et al. Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes. Nephrology, Dialysis, Transplantation. 2019; 34: 1864\u20131875.","DOI":"10.1093\/ndt\/gfy392"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Xie J, Yoon J, An SW, Kuro-o M, Huang CL. Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate. Journal of the American Society of Nephrology. 2015; 26: 1150\u20131160.","DOI":"10.1681\/ASN.2014040325"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Junho CVC, Gonz\u00e1lez-Lafuente L, Neres-Santos RS, Navarro-Garc\u00eda JA, Rodr\u00edguez-S\u00e1nchez E, Ruiz-Hurtado G, et al. Klotho relieves inflammation and exerts a cardioprotective effect during renal ischemia\/reperfusion-induced cardiorenal syndrome. Biomedicine & Pharmacotherapy. 2022; 153: 113515.","DOI":"10.1016\/j.biopha.2022.113515"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney International. 2009; 75: 890\u2013897.","DOI":"10.1038\/ki.2008.644"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Lu L, Liu X, Gong Y, Zhou X, Chen A, Li M, et al. STING Facilitates Vascular Calcification via p-STAT1\/NLRP3 Signal. FASEB Journal. 2025; 39: e70530.","DOI":"10.1096\/fj.202403334R"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, Deo R, Herzog CA, et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. European Heart Journal. 2018; 39: 2314\u20132325.","DOI":"10.1093\/eurheartj\/ehy060"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"King BMN, Mintz S, Lin X, Morley GE, Schlamp F, Khodadadi-Jamayran A, et al. Chronic Kidney Disease Induces Proarrhythmic Remodeling. Circulation. Arrhythmia and Electrophysiology. 2023; 16: e011466.","DOI":"10.1161\/CIRCEP.122.011466"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Graves JM, Vallejo JA, Hamill CS, Wang D, Ahuja R, Patel S, et al. Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner. American Journal of Physiology. Heart and Circulatory Physiology. 2021; 320: H2283\u2013H2294.","DOI":"10.1152\/ajpheart.00798.2020"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Hsueh CH, Chen NX, Lin SF, Chen PS, Gattone VH 2nd, Allen MR, et al. Pathogenesis of arrhythmias in a model of CKD. Journal of the American Society of Nephrology. 2014; 25: 2812\u20132821.","DOI":"10.1681\/ASN.2013121343"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Dhingra R, Gaziano JM, Djouss\u00e9 L. Chronic kidney disease and the risk of heart failure in men. Circulation. Heart Failure. 2011; 4: 138\u2013144.","DOI":"10.1161\/CIRCHEARTFAILURE.109.899070"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. Journal of the American Society of Nephrology. 2007; 18: 1307\u20131315.","DOI":"10.1681\/ASN.2006101159"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Hassan MB, Siddique S, Maheshwari SK, Neelam F, Neha F, Lohana B, et al. Chronic kidney disease and cardiovascular risk: Pathophysiology and interventional approaches - systematic review. Medicine. 2025; 104: e46189.","DOI":"10.1097\/MD.0000000000046189"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Stellmacher L, K\u00f6nig S, Leiner J, Pellissier V, Hohenstein S, Birnbaum J, et al. CaReMe-CKD-HF-Epidemiology of Heart Failure in Chronic Kidney Disease: A Retrospective Analysis of Routine Administrative Data from a German Hospital Network. Journal of Cardiovascular Development and Disease. 2025; 12: 448.","DOI":"10.3390\/jcdd12110448"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Beck H, Titze SI, H\u00fcbner S, Busch M, Schlieper G, Schultheiss UT, et al. Heart failure in a cohort of patients with chronic kidney disease: the GCKD study. PLoS ONE. 2015; 10: e0122552.","DOI":"10.1371\/journal.pone.0122552"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Sundstr\u00f6m J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2\u00b74 million patients from 11 countries: The CaReMe CKD study. The Lancet Regional Health. Europe. 2022; 20: 100438.","DOI":"10.1016\/j.lanepe.2022.100438"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Yu AS, Pak KJ, Zhou H, Shaw SF, Shi J, Broder BI, et al. All-Cause and Cardiovascular-Related Mortality in CKD Patients With and Without Heart Failure: A Population-Based Cohort Study in Kaiser Permanente Southern California. Kidney Medicine. 2023; 5: 100624.","DOI":"10.1016\/j.xkme.2023.100624"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Loutradis C, Sarafidis PA, Ferro CJ, Zoccali C. Volume overload in hemodialysis: diagnosis, cardiovascular consequences, and management. Nephrology, Dialysis, Transplantation. 2021; 36: 2182\u20132193.","DOI":"10.1093\/ndt\/gfaa182"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Arrigo M, Von Moos S, Gerritsen K, Sadoune M, Tangvoraphonkchai K, Davenport A, et al. Soluble CD146 and B-type natriuretic peptide dissect overhydration into functional components of prognostic relevance in haemodialysis patients. Nephrology, Dialysis, Transplantation. 2018; 33: 2035\u20132042.","DOI":"10.1093\/ndt\/gfy113"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Salerno FR, Parraga G, McIntyre CW. Why Is Your Patient Still Short of Breath? Understanding the Complex Pathophysiology of Dyspnea in Chronic Kidney Disease. Seminars in Dialysis. 2017; 30: 50\u201357.","DOI":"10.1111\/sdi.12548"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Kim SM, Jeong Y, Kim YL, Kang M, Kang E, Ryu H, et al. Association of Chronic Kidney Disease With Atrial Fibrillation in the General Adult Population: A Nationwide Population-Based Study. Journal of the American Heart Association. 2023; 12: e028496.","DOI":"10.1161\/JAHA.122.028496"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"McManus DD, Saczynski JS, Ward JA, Jaggi K, Bourrell P, Darling C, et al. The Relationship Between Atrial Fibrillation and Chronic Kidney Disease : Epidemiologic and Pathophysiologic Considerations for a Dual Epidemic. Journal of Atrial Fibrillation. 2012; 5: 442.","DOI":"10.4022\/jafib.442"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Rankinen J, Hernesniemi J, Tynkkynen JT. Atrial fibrillation and the risk of sudden cardiac death: incidence, impact and implications. Heart. 2026; 112: 375\u2013382.","DOI":"10.1136\/heartjnl-2025-326003"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Di Lullo L, Rivera R, Barbera V, Bellasi A, Cozzolino M, Russo D, et al. Sudden cardiac death and chronic kidney disease: From pathophysiology to treatment strategies. International Journal of Cardiology. 2016; 217: 16\u201327.","DOI":"10.1016\/j.ijcard.2016.04.170"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Wang AYM, Lam CWK, Chan IHS, Wang M, Lui SF, Sanderson JE. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. Hypertension. 2010; 56: 210\u2013216.","DOI":"10.1161\/HYPERTENSIONAHA.110.151167"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Truyen TTTT, Uy-Evanado A, Chugh H, Reinier K, Charytan DM, Salvucci A, et al. Moderate Kidney Dysfunction Independently Increases Sudden Cardiac Arrest Risk: A Community-Based Study. Journal of the American Heart Association. 2025; 14: e042307.","DOI":"10.1161\/JAHA.125.042307"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Kalra PA, Green D, Poulikakos D. Arrhythmia in hemodialysis patients and its relation to sudden death. Kidney International. 2018; 93: 781\u2013783.","DOI":"10.1016\/j.kint.2017.12.005"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney International. 1995; 47: 186\u2013192.","DOI":"10.1038\/ki.1995.22"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Jameel FA, Junejo AM, Khan QUA, Date S, Faraz A, Rizvi SHM, et al. Echocardiographic Changes in Chronic Kidney Disease Patients on Maintenance Hemodialysis. Cureus. 2020; 12: e8969.","DOI":"10.7759\/cureus.8969"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. Journal of the American Society of Nephrology. 2012; 23: 1725\u20131734.","DOI":"10.1681\/ASN.2012020145"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Paoletti E, Bellino D, Gallina AM, Amidone M, Cassottana P, Cannella G. Is left ventricular hypertrophy a powerful predictor of progression to dialysis in chronic kidney disease? Nephrology, Dialysis, Transplantation. 2011; 26: 670\u2013677.","DOI":"10.1093\/ndt\/gfq409"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. American Journal of Kidney Diseases. 2005; 46: 320\u2013327.","DOI":"10.1053\/j.ajkd.2005.04.031"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"Haberka M, Starzak M, Smolka G, Wojakowski W, G\u0105sior Z. Echocardiography and Cardiac Magnetic Resonance in the Assessment of Left-Ventricle Remodeling: Differences Implying Clinical Decision. Journal of Clinical Medicine. 2024; 13: 1620.","DOI":"10.3390\/jcm13061620"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"Mark PB, Johnston N, Groenning BA, Foster JE, Blyth KG, Martin TN, et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney International. 2006; 69: 1839\u20131845.","DOI":"10.1038\/sj.ki.5000249"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Perea RJ, Ortiz-Perez JT, Sole M, Cibeira MT, de Caralt TM, Prat-Gonzalez S, et al. T1 mapping: characterisation of myocardial interstitial space. Insights into Imaging. 2015; 6: 189\u2013202.","DOI":"10.1007\/s13244-014-0366-9"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"Zhang C, Yao L, Liu M, Zhou Y. Features of cardiovascular magnetic resonance native T1 mapping in maintenance hemodialysis patients and their related factors. Renal Failure. 2024; 46: 2310078.","DOI":"10.1080\/0886022X.2024.2310078"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Graham-Brown MPM, March DS, Churchward DR, Stensel DJ, Singh A, Arnold R, et al. Novel cardiac nuclear magnetic resonance method for noninvasive assessment of myocardial fibrosis in hemodialysis patients. Kidney International. 2016; 90: 835\u2013844.","DOI":"10.1016\/j.kint.2016.07.014"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Graham-Brown MPM, Gulsin GS, Poli F, Parke K, Burton JO, McCann GP. Differences in native T1 and native T2 mapping between patients on hemodialysis and control subjects. European Journal of Radiology. 2021; 140: 109748.","DOI":"10.1016\/j.ejrad.2021.109748"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"Qin L, Gu S, Xiao R, Liu P, Yan F, Yu H, et al. Value of native T1 mapping in the prediction of major adverse cardiovascular events in hemodialysis patients. European Radiology. 2022; 32: 6878\u20136890.","DOI":"10.1007\/s00330-022-08839-8"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"Chen C, Hsu YC, Chou KW, Chang KS, Hsu YH, Chiu WH, et al. NT-proBNP point-of-care testing for predicting mortality in end-stage renal disease: A survival analysis. Heliyon. 2024; 10: e30581.","DOI":"10.1016\/j.heliyon.2024.e30581"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A, et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney International. 2001; 59: 1559\u20131566.","DOI":"10.1046\/j.1523-1755.2001.0590041559.x"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"Hayashida H, Haruyama N, Fukui A, Yoshitomi R, Fujisawa H, Nakayama M. Plasma B-type natriuretic peptide is independently associated with cardiovascular events and mortality in patients with chronic kidney disease. Scientific Reports. 2024; 14: 16542.","DOI":"10.1038\/s41598-024-67529-1"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"Sun L, Tan X, Cao X, Zou J. Assessed value of high-sensitivity cardiac troponin T for cardiovascular disease among CKD patients. Renal Failure. 2016; 38: 728\u2013737.","DOI":"10.3109\/0886022X.2016.1158040"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"Goicoechea M, Garca de Vinuesa S, G\u00f3mez-Campder\u00e1 F, Gutierrez MJ, Blanco P, Amann R, et al. Clinical significance of cardiac troponin T levels in chronic kidney disease patients: predictive value for cardiovascular risk. American Journal of Kidney Diseases. 2004; 43: 846\u2013853.","DOI":"10.1053\/j.ajkd.2003.12.048"},{"key":"ref119","doi-asserted-by":"publisher","unstructured":"Jiang MY, Wu WS. Association between high-sensitivity troponin and mortality risk in individuals with early kidney disease: A population-based cohort study. Medicine. 2025; 104: e43014.","DOI":"10.1097\/MD.0000000000043014"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"Ureche C, Dodi G, Covic A, Nedelcu A, Volov\u0103\u021b SR, Sasc\u0103u RA, et al. Connection between Cardiac Fibrosis Biomarkers and Echocardiography Parameters in Advanced Chronic Kidney Disease Patients. Journal of Clinical Medicine. 2023; 12: 3003.","DOI":"10.3390\/jcm12083003"},{"key":"ref121","doi-asserted-by":"publisher","unstructured":"Salib M, Girerd S, Girerd N, M\u00e4rz W, Scharnagl H, Massy ZA, et al. Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial. Clinical Research in Cardiology. 2022; 111: 614\u2013626.","DOI":"10.1007\/s00392-021-01898-9"},{"key":"ref122","doi-asserted-by":"publisher","unstructured":"Zhao Y, Du D, Chen S, Chen Z, Zhao J. New Insights into the Functions of MicroRNAs in Cardiac Fibrosis: From Mechanisms to Therapeutic Strategies. Genes. 2022; 13: 1390.","DOI":"10.3390\/genes13081390"},{"key":"ref123","doi-asserted-by":"publisher","unstructured":"Motshwari DD, Matshazi DM, Erasmus RT, Kengne AP, Matsha TE, George C. MicroRNAs Associated with Chronic Kidney Disease in the General Population and High-Risk Subgroups-A Systematic Review. International Journal of Molecular Sciences. 2023; 24: 1792.","DOI":"10.3390\/ijms24021792"},{"key":"ref124","doi-asserted-by":"publisher","unstructured":"Bolignano D, Greco M, Presta P, Duni A, Vita C, Pappas E, et al. A small circulating miRNAs signature predicts mortality and adverse cardiovascular outcomes in chronic hemodialysis patients. Clinical Kidney Journal. 2023; 16: 868\u2013878.","DOI":"10.1093\/ckj\/sfad017"},{"key":"ref125","doi-asserted-by":"publisher","unstructured":"Wen P, Song D, Ye H, Wu X, Jiang L, Tang B, et al. Circulating MiR-133a as a biomarker predicts cardiac hypertrophy in chronic hemodialysis patients. PLoS ONE. 2014; 9: e103079.","DOI":"10.1371\/journal.pone.0103079"},{"key":"ref126","doi-asserted-by":"publisher","unstructured":"Kov\u00e1cs ZZA, Sz\u0171cs G, Freiwan M, Kov\u00e1cs MG, M\u00e1rv\u00e1nyk\u00f6vi FM, Dinh H, et al. Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy. Scientific Reports. 2021; 11: 17495.","DOI":"10.1038\/s41598-021-96815-5"},{"key":"ref127","doi-asserted-by":"publisher","unstructured":"Ham O, Jin W, Lei L, Huang HH, Tsuji K, Huang M, et al. Pathological cardiac remodeling occurs early in CKD mice from unilateral urinary obstruction, and is attenuated by Enalapril. Scientific Reports. 2018; 8: 16087.","DOI":"10.1038\/s41598-018-34216-x"},{"key":"ref128","doi-asserted-by":"publisher","unstructured":"Leader CJ, Wilkins GT, Walker RJ. The effect of spironolactone on cardiac and renal fibrosis following myocardial infarction in established hypertension in the transgenic Cyp1a1Ren2 rat. PLoS ONE. 2021; 16: e0260554.","DOI":"10.1371\/journal.pone.0260554"},{"key":"ref129","doi-asserted-by":"publisher","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, B\u00e4rfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. Journal of Cardiovascular Pharmacology. 2014; 64: 69\u201378.","DOI":"10.1097\/FJC.0000000000000091"},{"key":"ref130","doi-asserted-by":"publisher","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European Heart Journal. 2022; 43: 474\u2013484.","DOI":"10.1093\/eurheartj\/ehab777"},{"key":"ref131","doi-asserted-by":"publisher","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England Journal of Medicine. 2024; 391: 1475\u20131485.","DOI":"10.1056\/NEJMoa2407107"},{"key":"ref132","doi-asserted-by":"publisher","unstructured":"Filippatos G, Anker SD, Bakris GL, Rossing P, Ruilope LM, Coats AJS, et al. Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes. ESC Heart Failure. 2025; 12: 185\u2013188.","DOI":"10.1002\/ehf2.14962"},{"key":"ref133","doi-asserted-by":"publisher","unstructured":"Karakasis P, Patoulias D, Popovic DS, Pamporis K, Theofilis P, Nasoufidou A, et al. Effects of mineralocorticoid receptor antagonists on new-onset or recurrent atrial fibrillation: a Bayesian and frequentist network meta-analysis of randomized trials. Current Problems in Cardiology. 2024; 49: 102742.","DOI":"10.1016\/j.cpcardiol.2024.102742"},{"key":"ref134","doi-asserted-by":"publisher","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. The New England Journal of Medicine. 2014; 371: 993\u20131004.","DOI":"10.1056\/NEJMoa1409077"},{"key":"ref135","doi-asserted-by":"publisher","unstructured":"Ruilope LM, Dukat A, B\u00f6hm M, Lacourci\u00e8re Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010; 375: 1255\u20131266.","DOI":"10.1016\/S0140-6736(09)61966-8"},{"key":"ref136","doi-asserted-by":"publisher","unstructured":"Chang HY, Lin CC, Chao CJ, Lin YC, Wang YC, Liao CT, et al. Real-World Experience of Angiotensin Receptor-Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease. Mayo Clinic Proceedings. 2023; 98: 88\u201399.","DOI":"10.1016\/j.mayocp.2022.06.007"},{"key":"ref137","doi-asserted-by":"publisher","unstructured":"Chinnappa S, Maqbool A, Viswambharan H, Mooney A, Denby L, Drinkhill M. Beta Blockade Prevents Cardiac Morphological and Molecular Remodelling in Experimental Uremia. International Journal of Molecular Sciences. 2023; 25: 373.","DOI":"10.3390\/ijms25010373"},{"key":"ref138","doi-asserted-by":"publisher","unstructured":"Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrology, Dialysis, Transplantation. 2014; 29: 672\u2013681.","DOI":"10.1093\/ndt\/gft515"},{"key":"ref139","doi-asserted-by":"publisher","unstructured":"Hohl M, Selejan SR, Wintrich J, Lehnert U, Speer T, Schneider C, et al. Renal Denervation Prevents Atrial Arrhythmogenic Substrate Development in CKD. Circulation Research. 2022; 130: 814\u2013828.","DOI":"10.1161\/CIRCRESAHA.121.320104"},{"key":"ref140","doi-asserted-by":"publisher","unstructured":"Law JP, Pickup L, Pavlovic D, Townend JN, Ferro CJ. Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations. Journal of Human Hypertension. 2023; 37: 1\u201319.","DOI":"10.1038\/s41371-022-00751-4"},{"key":"ref141","doi-asserted-by":"publisher","unstructured":"Maki KC, Wilcox ML, Dicklin MR, Kakkar R, Davidson MH. Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis. BMC Nephrology. 2022; 23: 34.","DOI":"10.1186\/s12882-022-02666-1"},{"key":"ref142","doi-asserted-by":"publisher","unstructured":"Kurella Tamura M, Huang M, An J, Zhou M, Niu F, Sim JJ, et al. SPRINT Treatment Among Adults With Chronic Kidney Disease From 2 Large Health Care Systems. JAMA Network Open. 2025; 8: e2453458.","DOI":"10.1001\/jamanetworkopen.2024.53458"},{"key":"ref143","doi-asserted-by":"publisher","unstructured":"Grigoriou K, Karakasis P, Nasoufidou A, Stachteas P, Klisic A, Karagiannidis E, et al. SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era. Medicina. 2025; 61: 1903.","DOI":"10.3390\/medicina61111903"},{"key":"ref144","doi-asserted-by":"publisher","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes, Obesity & Metabolism. 2013; 15: 853\u2013862.","DOI":"10.1111\/dom.12127"},{"key":"ref145","doi-asserted-by":"publisher","unstructured":"List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009; 32: 650\u2013657.","DOI":"10.2337\/dc08-1863"},{"key":"ref146","doi-asserted-by":"publisher","unstructured":"Adam CA, Anghel R, Marcu DTM, Mitu O, Roca M, Mitu F. Impact of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging-What Do We Know So Far? (A Narrative Review). Life. 2022; 12: 803.","DOI":"10.3390\/life12060803"},{"key":"ref147","doi-asserted-by":"publisher","unstructured":"Herat LY, Magno AL, Rudnicka C, Hricova J, Carnagarin R, Ward NC, et al. SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection. JACC. Basic to Translational Science. 2020; 5: 169\u2013179.","DOI":"10.1016\/j.jacbts.2019.11.007"},{"key":"ref148","doi-asserted-by":"publisher","unstructured":"Yaribeygi H, Maleki M, Butler AE, Jamialahmadi T, Sahebkar A. Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art. EXCLI Journal. 2023; 22: 53\u201366.","DOI":"10.17179\/excli2022-5482"},{"key":"ref149","doi-asserted-by":"publisher","unstructured":"Packer M. Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling\/Autophagy Hypothesis. Circulation. 2022; 146: 1383\u20131405.","DOI":"10.1161\/CIRCULATIONAHA.122.061732"},{"key":"ref150","doi-asserted-by":"publisher","unstructured":"Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016; 65: 1190\u20131195.","DOI":"10.2337\/db15-1356"},{"key":"ref151","doi-asserted-by":"publisher","unstructured":"Yang X, Liu Q, Li Y, Tang Q, Wu T, Chen L, et al. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1\u03b1 signalling pathway. Adipocyte. 2020; 9: 484\u2013494.","DOI":"10.1080\/21623945.2020.1807850"},{"key":"ref152","doi-asserted-by":"publisher","unstructured":"Rykova EY, Klimontov VV, Shmakova E, Korbut AI, Merkulova TI, Kzhyshkowska J. Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages. International Journal of Molecular Sciences. 2025; 26: 1670.","DOI":"10.3390\/ijms26041670"},{"key":"ref153","doi-asserted-by":"publisher","unstructured":"Gohari S, Ismail-Beigi F, Mahjani M, Ghobadi S, Jafari A, Ahangar H, et al. The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials. BMC Endocrine Disorders. 2023; 23: 257.","DOI":"10.1186\/s12902-023-01512-1"},{"key":"ref154","doi-asserted-by":"publisher","unstructured":"Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nature Communications. 2020; 11: 2127.","DOI":"10.1038\/s41467-020-15983-6"},{"key":"ref155","doi-asserted-by":"publisher","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine. 2020; 383: 1436\u20131446.","DOI":"10.1056\/NEJMoa2024816"},{"key":"ref156","doi-asserted-by":"publisher","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England Journal of Medicine. 2021; 385: 1451\u20131461.","DOI":"10.1056\/NEJMoa2107038"},{"key":"ref157","doi-asserted-by":"publisher","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine. 2019; 381: 1995\u20132008.","DOI":"10.1056\/NEJMoa1911303"},{"key":"ref158","doi-asserted-by":"publisher","unstructured":"Kongmalai T, Hadnorntun P, Leelahavarong P, Kongmalai P, Srinonprasert V, Chirakarnjanakorn S, et al. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials. Frontiers in Endocrinology. 2023; 14: 1216160.","DOI":"10.3389\/fendo.2023.1216160"},{"key":"ref159","doi-asserted-by":"publisher","unstructured":"Ros\u00e9n HC, Mohammad MA, Jernberg T, James S, Oldgren J, Erlinge D. SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART. The Lancet Regional Health. Europe. 2024; 45: 101032.","DOI":"10.1016\/j.lanepe.2024.101032"},{"key":"ref160","doi-asserted-by":"publisher","unstructured":"Pabel S, Wagner S, Bollenberg H, Bengel P, Kov\u00e1cs \u00c1, Schach C, et al. Empagliflozin directly improves diastolic function in human heart failure. European Journal of Heart Failure. 2018; 20: 1690\u20131700.","DOI":"10.1002\/ejhf.1328"},{"key":"ref161","doi-asserted-by":"publisher","unstructured":"Yang Q, Wang C, Wang W, Li Y, Dang Y. The preventive effect of sodium-glucose co-transporter-2 inhibitors on atrial fibrillation and atrial flutter in patients with chronic kidney disease: a meta-analysis. Frontiers in Pharmacology. 2025; 16: 1585491.","DOI":"10.3389\/fphar.2025.1585491"},{"key":"ref162","doi-asserted-by":"publisher","unstructured":"Karakasis P, Patoulias D, Theofilis P, Pamporis K, Sagris M, Vlachakis PK, et al. GLP-1 Receptor Agonists and Myocardial Perfusion: Bridging Mechanisms to Clinical Outcomes. International Journal of Molecular Sciences. 2025; 26: 3050.","DOI":"10.3390\/ijms26073050"},{"key":"ref163","doi-asserted-by":"publisher","unstructured":"Waqas SA, Sohail MU, Saad M, Minhas AMK, Greene SJ, Fudim M, et al. Efficacy of GLP-1 Receptor Agonists in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. Journal of Cardiac Failure. 2025; 31: 1076\u20131080.","DOI":"10.1016\/j.cardfail.2025.01.022"},{"key":"ref164","doi-asserted-by":"publisher","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England Journal of Medicine. 2024; 391: 109\u2013121.","DOI":"10.1056\/NEJMoa2403347"},{"key":"ref165","doi-asserted-by":"publisher","unstructured":"Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nature Medicine. 2024; 30: 2849\u20132856.","DOI":"10.1038\/s41591-024-03133-0"},{"key":"ref166","doi-asserted-by":"publisher","unstructured":"Karakasis P, Vlachos K, Antoniadis AP, Siontis KC, Patoulias D, Fragakis N, et al. Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism: Clinical and Experimental. 2026; 175: 156463.","DOI":"10.1016\/j.metabol.2025.156463"},{"key":"ref167","doi-asserted-by":"publisher","unstructured":"Varga CR, Cleland JGF, Abraham WT, Lip GYH, Leyva F, Hatamizadeh P. Implantable Cardioverter Defibrillator and Resynchronization Therapy in Patients With Overt Chronic Kidney Disease: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2024; 84: 1342\u20131362.","DOI":"10.1016\/j.jacc.2024.05.081"},{"key":"ref168","doi-asserted-by":"publisher","unstructured":"Bansal N, Szpiro A, Reynolds K, Smith DH, Magid DJ, Gurwitz JH, et al. Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease. JAMA Internal Medicine. 2018; 178: 390\u2013398.","DOI":"10.1001\/jamainternmed.2017.8462"},{"key":"ref169","doi-asserted-by":"publisher","unstructured":"Jukema JW, Timal RJ, Rotmans JI, Hensen LCR, Buiten MS, de Bie MK, et al. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients. Circulation. 2019; 139: 2628\u20132638.","DOI":"10.1161\/CIRCULATIONAHA.119.039818"},{"key":"ref170","doi-asserted-by":"publisher","unstructured":"H\u00f6ke U, Khidir MJH, van der Velde ET, Schalij MJ, Bax JJ, Delgado V, et al. Cardiac Resynchronization Therapy in CKD Stage 4 Patients. Clinical Journal of the American Society of Nephrology. 2015; 10: 1740\u20131748.","DOI":"10.2215\/CJN.00620115"},{"key":"ref171","doi-asserted-by":"publisher","unstructured":"Pickup LC, Law JP, Radhakrishnan A, Price AM, Loutradis C, Smith TO, et al. Changes in left ventricular structure and function associated with renal transplantation: a systematic review and meta-analysis. ESC Heart Failure. 2021; 8: 2045\u20132057.","DOI":"10.1002\/ehf2.13283"},{"key":"ref172","doi-asserted-by":"publisher","unstructured":"Tian Z, Bergmann K, Kaufeld J, Schmidt-Ott K, Melk A, Schmidt BMW. Left Ventricular Hypertrophy After Renal Transplantation: Systematic Review and Meta-analysis. Transplantation Direct. 2024; 10: e1647.","DOI":"10.1097\/TXD.0000000000001647"},{"key":"ref173","doi-asserted-by":"publisher","unstructured":"Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clinical Journal of the American Society of Nephrology. 2009; 4: 755\u2013762.","DOI":"10.2215\/CJN.02730608"},{"key":"ref174","doi-asserted-by":"publisher","unstructured":"Kosugi T, Hasegawa T, Imaizumi T, Nishiwaki H, Honda H, Ito Y, et al. Association between hemoglobin level and mortality in patients undergoing maintenance hemodialysis: a nationwide dialysis registry in Japan. Clinical and Experimental Nephrology. 2025; 29: 831\u2013842.","DOI":"10.1007\/s10157-025-02632-9"},{"key":"ref175","doi-asserted-by":"publisher","unstructured":"Yagi S, Aihara KI, Ikeda Y, Akaike M, Sata M, Matsumoto T. Effects of statins on cardiorenal syndrome. International Journal of Vascular Medicine. 2012; 2012: 162545.","DOI":"10.1155\/2012\/162545"},{"key":"ref176","doi-asserted-by":"publisher","unstructured":"Theofilis P, Vlachakis PK, Karakasis P, Kalaitzidis RG. Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk. Current Atherosclerosis Reports. 2025; 27: 41.","DOI":"10.1007\/s11883-025-01290-2"},{"key":"ref177","doi-asserted-by":"publisher","unstructured":"Wanner C, Krane V, M\u00e4rz W, Olschewski M, Mann JFE, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. The New England Journal of Medicine. 2005; 353: 238\u2013248.","DOI":"10.1056\/NEJMoa043545"},{"key":"ref178","doi-asserted-by":"publisher","unstructured":"Fellstr\u00f6m BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. The New England Journal of Medicine. 2009; 360: 1395\u20131407.","DOI":"10.1056\/NEJMoa0810177"},{"key":"ref179","doi-asserted-by":"publisher","unstructured":"Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal. 2010; 160: 785\u2013794.e10.","DOI":"10.1016\/j.ahj.2010.08.012"},{"key":"ref180","doi-asserted-by":"publisher","unstructured":"Wilhelmi T, Xu X, Tan X, Hulshoff MS, Maamari S, Sossalla S, et al. Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1. Theranostics. 2020; 10: 3905\u20133924.","DOI":"10.7150\/thno.38640"},{"key":"ref181","doi-asserted-by":"publisher","unstructured":"Giam B, Chu PY, Kuruppu S, Smith AI, Horlock D, Murali A, et al. Serelaxin attenuates renal inflammation and fibrosis in a mouse model of dilated cardiomyopathy. Experimental Physiology. 2018; 103: 1593\u20131602.","DOI":"10.1113\/EP087189"},{"key":"ref182","doi-asserted-by":"publisher","unstructured":"Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013; 381: 29\u201339.","DOI":"10.1016\/S0140-6736(12)61855-8"},{"key":"ref183","doi-asserted-by":"publisher","unstructured":"Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, et al. Effects of Serelaxin in Patients with Acute Heart Failure. The New England Journal of Medicine. 2019; 381: 716\u2013726.","DOI":"10.1056\/NEJMoa1801291"},{"key":"ref184","doi-asserted-by":"publisher","unstructured":"Silva TA, Thomas D, Siqueira-Neto JL, Calvet CM. Pirfenidone Prevents Heart Fibrosis during Chronic Chagas Disease Cardiomyopathy. International Journal of Molecular Sciences. 2024; 25: 7302.","DOI":"10.3390\/ijms25137302"},{"key":"ref185","doi-asserted-by":"publisher","unstructured":"Lewis GA, Dodd S, Clayton D, Bedson E, Eccleson H, Schelbert EB, et al. Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nature Medicine. 2021; 27: 1477\u20131482.","DOI":"10.1038\/s41591-021-01452-0"},{"key":"ref186","doi-asserted-by":"publisher","unstructured":"Takakura K, Mizukami K, Mitori H, Noto T, Tomura Y. Antiproteinuric effect of pirfenidone in a rat model of anti-glomerular basement membrane glomerulonephritis. European Journal of Pharmacology. 2014; 737: 106\u2013116.","DOI":"10.1016\/j.ejphar.2014.05.015"},{"key":"ref187","doi-asserted-by":"publisher","unstructured":"Song Q, Wang P, Wu Y, Yao Z, Wang W, Tang G, et al. Understanding uremic cardiomyopathy: from pathogenesis to diagnosis and the horizon of therapeutic innovations. PeerJ. 2025; 13: e18978.","DOI":"10.7717\/peerj.18978"},{"key":"ref188","doi-asserted-by":"publisher","unstructured":"S\u00e1rk\u00f6zy M, Watzinger S, Kov\u00e1cs ZZA, Acar E, M\u00e1rv\u00e1nyk\u00f6vi F, Sz\u0171cs G, et al. Neuregulin-1\u03b2 Improves Uremic Cardiomyopathy and Renal Dysfunction in Rats. JACC. Basic to Translational Science. 2023; 8: 1160\u20131176.","DOI":"10.1016\/j.jacbts.2023.03.003"},{"key":"ref189","doi-asserted-by":"publisher","unstructured":"Nowak KL, Chonchol M, Ikizler TA, Farmer-Bailey H, Salas N, Chaudhry R, et al. IL-1 Inhibition and Vascular Function in CKD. Journal of the American Society of Nephrology. 2017; 28: 971\u2013980.","DOI":"10.1681\/ASN.2016040453"},{"key":"ref190","doi-asserted-by":"publisher","unstructured":"Sato E, Saigusa D, Mishima E, Uchida T, Miura D, Morikawa-Ichinose T, et al. Impact of the Oral Adsorbent AST-120 on Organ-Specific Accumulation of Uremic Toxins: LC-MS\/MS and MS Imaging Techniques. Toxins. 2017; 10: 19.","DOI":"10.3390\/toxins10010019"},{"key":"ref191","doi-asserted-by":"publisher","unstructured":"Liao J, Xiong Q, Yin Y, Ling Z, Chen S. The Effects of Fish Oil on Cardiovascular Diseases: Systematical Evaluation and Recent Advance. Frontiers in Cardiovascular Medicine. 2022; 8: 802306.","DOI":"10.3389\/fcvm.2021.802306"},{"key":"ref192","doi-asserted-by":"publisher","unstructured":"Lok CE, Farkouh M, Hemmelgarn BR, Moist LM, Polkinghorne KR, Tomlinson G, et al. Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. The New England Journal of Medicine. 2026; 394: 128\u2013137.","DOI":"10.1056\/NEJMoa2513032"},{"key":"ref193","doi-asserted-by":"publisher","unstructured":"Agoro R, Montagna A, Goetz R, Aligbe O, Singh G, Coe LM, et al. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. FASEB Journal. 2018; 32: 3752\u20133764.","DOI":"10.1096\/fj.201700667R"},{"key":"ref194","doi-asserted-by":"publisher","unstructured":"Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, et al. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024; 149: 450\u2013462.","DOI":"10.1161\/CIRCULATIONAHA.123.067584"}],"container-title":["British Journal of Hospital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/7\/10.31083\/BJHM51534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:00:04Z","timestamp":1785398404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/7\/10.31083\/BJHM51534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":194,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1750-8460(26)03312-0"],"URL":"https:\/\/doi.org\/10.31083\/bjhm51534","relation":{},"ISSN":["1750-8460","1759-7390"],"issn-type":[{"value":"1750-8460","type":"print"},{"value":"1759-7390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"51534"}}